Healthcare professionals should adopt a risk-stratified approach when determining monitoring frequency
Draw up the diluent: Using a clean syringe, draw the calculated volume of bacteriostatic water
Disclosure: Compounded GLP-1 medications are not reviewed or approved by the FDA for safety, efficacy, or quality and may vary in potency and formulation
While all GLP-1 receptor agonists effectively lower hemoglobin A1c and promote weight loss, there are meaningful differences in their magnitude of effect, titration schedules, and adverse effect profiles that influence clinical decision-making
If had we not brought the lawsuit, I think it would have been one of those situations that they made the rule, nobody fought it, so they just kind of went on down the road and just said, this is the way that it's going to be," says Dan DeNeui, CEO of EVEXIAS Life Sciences & Managing Partner of FarmaKeio Pharmacy Network
Industry trackers have estimated a possible NDA submission in late 2026 or early 2027 based on the pace of Phase 3 readouts, with potential approval roughly ten months after submission under standard review but Eli Lilly has not published an official timeline, and it depends on the outcome of the remaining TRIUMPH trials
.png.jpg)
